Astex Pharmaceuticals Withdraws From Upcoming Investor Conferences

DUBLIN, Calif., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that management team members will not participate at three banking conferences at which the company had previously planned to present. The three are the Rodman & Renshaw Annual Global Investment Conference, the Morgan Stanley Global Healthcare Conference, and the Stifel Healthcare Conference 2013.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
CONTACT: Timothy L. Enns         Astex Pharmaceuticals, Inc.         Senior Vice President         Corporate Communications & Marketing         Tel: +1 (925) 560-2810         E-mail: tim.enns@astx.com                  Susanna Chau         Astex Pharmaceuticals, Inc.         Manager         Investor Relations         Tel: +1 (925) 560-2845         E-mail: susanna.chau@astx.com                  Alan Roemer         The Trout Group         Managing Director         Tel: +1 (646) 378-2945         E-mail: aroemer@troutgroup.com

Astex Pharmaceuticals, Inc. logo